Airway diseases
Oral presentation
Novel drug targets for asthma and COPD
Methods :
General respiratory patient care, Physiology
08:30
Late Breaking Abstract - RPL554, a first-in-class dual PDE3/4 inhibitor, causes significant bronchodilation and symptom relief; a Phase 2b COPD study
D. Singh(Manchester, United Kingdom)
COI
1
08:45
Anti-inflammatory effects of the JAK inhibitor tofacitinib in two murine house dust mite -driven models of asthma.
A. Pisano(Parma (PR), Italy)
COI
2
09:00
Hydrogen sulphide donors prevent hyperreactivity of mice tracheas in an in vitro lipopolysaccharide-induced inflammation model
Y. Karaman(Ankara, Turkey)
COI
3
09:15
Aerosolized TLR7 Imidazoquinoline Agonist Bronchodilates In Vivo
M. Drake(Portland, United States)
COI
4
09:30
IL-33 blockade impacts mediators of persistence and exacerbation of chronic airway inflammation.
J. Allinne(Tarrytown, United States)
COI
5
09:45
Targeting NADPH oxidase-2 reduces cigarette smoke-induced lung inflammation and skeletal muscle wasting in mice
I. Bernardo(Melbourne (VIC), Australia)
COI
6
10:00
Efficacy of a novel PI3Kd inhibitor, DS-1515 in animal models of asthma
M. Suzuki(Tokyo, Japan)
COI
7
. . .
